

## Disclosure of Value Transfers

### Methodological Note

<b>Country</b>	United Kingdom
----------------	----------------

<b>Entity Name</b>	Mylan UK Healthcare Limited
--------------------	-----------------------------

<b>Legal Basis for Disclosure</b>	Medicines for Europe Code of Conduct on Interactions with the Healthcare Community, published February 2015 Updated in January 2016
-----------------------------------	---

<b>Reporting Period</b>	2020
-------------------------	------

<b>Currency of disclosed values</b>	<p>All values are disclosed in</p> <p><input type="checkbox"/> EUR</p> <p><input checked="" type="checkbox"/> Pound sterling</p>
-------------------------------------	--

<b>Value identification and Recognition</b>	All values disclosed are based on value transfers actually made within the respective category. Such value transfers have been made to a specific recipient as booked in the respective reporting period.
---	---

<b>Multi-Year Contracts</b>	Value transfers under multiyear contracts are part of the disclosed data to the extent that actual value transfers have been made in the respective reporting period.
-----------------------------	---

<b>Data disclosed for</b>	<p>All values are disclosed for</p> <p><input checked="" type="checkbox"/> Recipients which have been engaged by entity</p> <p><input checked="" type="checkbox"/> Recipients which have their residence in the country</p>
---------------------------	---

<b>VAT and other taxes</b>	All amounts are disclosed include VAT or similar service taxes, where such apply on the transaction
----------------------------	---

<b>Disclosure location:</b>	[Link to company website or other disclosure location]
-----------------------------	--

<b>Value category: "Meetings, educational support and site visits of HCPs"</b>	<p>The company discloses value transfers in this category as per Option 2 of the Medicine for Europe Transparency Requirements:</p> <p>Aggregate total amount of support provided to Healthcare Professionals per individual conference or meeting as follows:</p>
--	--

---

## Disclosure of Value Transfers

---

	<ul style="list-style-type: none"><li>• Sponsorship for attending a third party organised congress (as per section 4.4):<ul style="list-style-type: none"><li>- name of congress,</li><li>- aggregated amount spent for the congress, including the</li><li>- number of Healthcare Professionals financially supported to attend</li></ul></li><li>• Site visits (as per section 4.5): aggregated amount spent, including the number of Healthcare Professionals financially supported to attend.</li><li>• Company organised meeting: aggregated amount spent, including the number of Healthcare Professionals financially supported to attend.</li></ul>
<b>Other Remarks</b>	<p>For value categories related to HCPs, aggregate values have been disclosed for 2020 following the advice provided by Medicines for Europe.</p> <p>Fees paid in connection with research &amp; development activities or market research have not been disclosed.</p>

---

<https://saas2-emea-ags.compltech.iqvia.com/aggregatespend360/>